Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epidaza QD vs BIW in Extranodal NK-T-Cell Lymphoma
NCT02878278Phase 2Unknown
- Start
- Sep 2016
- Primary completion
- Mar 2019
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial of tucidinostat in Extranodal NK/T-cell lymphoma (ENKTL). Status: unknown.
02
Drugs
tucidinostat
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT02878278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02878278.